Fig. 2.
Kaplan-Meier Curves regarding overall survival: a all patients, b first salvage versus > first salvage therapy, c hematologic versus molecular relapses. a Median survival of all patients (n = 32) was 3.7 months (CI 2.8–4.6). b Median survival of patients receiving HMAClax as first (n = 8) vs > first salvage therapy (n = 24) was 5.7 vs 3.4 months (p = n.s.). c Median survival of patients with MR (n = 6) vs HR (n = 26) (± XR) was not reached vs 3.4 months, p = 0.024